BioSpace News Archive

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the U.S. Food and Drug Administration (“FDA”) clearance of its Investigational New Drug (IND) application for DCR-AUD, the Company’s investigational RNAi candidate for the treatment of alcohol use disorder (AUD).

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus infection, as well as therapies to treat coronaviruses, announced that it has scheduled its second quarter 2021 financial results and corporate update for Thursday, August 5, 2021.

Genocea Biosciences, Inc., a biopharmaceutical company developing next-generation neoantigen immunotherapies, provided a business update for the second quarter ended June 30, 2021.

SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced that the company will be participating in the upcoming Canaccord Genuity 41st Annual Growth Conference.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the company will host a conference call and webcast to discuss its second quarter 2021 financial results on Monday, August 9, 2021 at 4:30 p.m. ET.

Cepheid announced that it has received CE-IVD clearance for Xpert® HIV-1 Viral Load XC and Xpert® HIV-1 Qual XC, next-generation extended-coverage tests for HIV testing.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021.

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced that it will report its second quarter 2021 financial results on Thursday, August 5, 2021, before the opening of the U.S. financial markets.

Blueprint Medicines Corporation reported financial results and provided a business update for the second quarter ended June 30, 2021.

Landos Biopharma, Inc (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced financial results for the second quarter ended June 30, 2021 and provided business updates.